[Modern Sonographic Imaging of Abdominal Neuroendocrine Tumors]

Overview

Journal Radiologe

Specialty Radiology

Date 2019 Aug 24

PMID 31440790

Citations 4

Authors

V Schwarze

C Marschner

S Grosu

J Rubenthaler

T Knosel

D-A Clevert

Affiliations

Soon will be listed here.

Abstract

Background: Radiological and nuclear medical diagnostics play an important role in the work-up of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). The sonographic examination, including contrast-enhanced examination, depicts an initial imaging modality to screen for NET. This report describes the sonomorphological behavior of ileal and pancreatic NET as well as hepatic metastases from NET.

Clinical/methodical Issue: Sonographic evaluation of NET of the small intestine, pancreas and neuroendocrine hepatic metastases.

Standard Radiological Methods: Contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), unenhanced ultrasonography.

Methodical Innovations: Contrast-enhanced ultrasound (CEUS).

Performance: CEUS supports unenhanced ultrasound in the detection of NET and the differential diagnosis of unclear lesions, and is more sensitive for liver metastases (sensitivity according to the literature, 99% vs. 68%) PRACTICAL RECOMMENDATIONS: CEUS allows initial evaluation of NET and differentiation of benign vs. malignant lesions. Nevertheless, CEUS cannot replace more elaborate imaging modalities like CT or MRI for thorough staging examinations.

Citing Articles

ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.

Ebner R, Sheikh G, Brendel M, Ricke J, Cyran C Eur Radiol. 2024; .

PMID: 39387873 DOI: 10.1007/s00330-024-11095-7.

[Imaging of pancreatic neuroendocrine tumors].

Berger F, Ingenerf M, Auernhammer C, Cyran C, Ebner R, Zacherl M Radiologie (Heidelb). 2024; 64(7):559-567.

PMID: 38789854 DOI: 10.1007/s00117-024-01316-x.

[Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology].

Ebner R, Rubenthaler J, Ricke J, Sheikh G, Unterrainer L, Auernhammer C Radiologie (Heidelb). 2024; 64(7):553-558.

PMID: 38713221 DOI: 10.1007/s00117-024-01296-y.

High-frame-rate contrast-enhanced ultrasound findings of liver metastasis of duodenal gastrointestinal stromal tumor: A case report and literature review.

Chen J, Huang Y World J Clin Cases. 2022; 10(17):5899-5909.

PMID: 35979134 PMC: 9258392. DOI: 10.12998/wjcc.v10.i17.5899.

References

Piscaglia F, Bolondi L . The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006; 32(9):1369-75. DOI: 10.1016/j.ultrasmedbio.2006.05.031. View

. Abdominal applications of ultrasound fusion imaging technique: liver, kidney, and pancreas. Insights Imaging. 2019; 10(1):6. PMC: 6352389. DOI: 10.1186/s13244-019-0692-z. View

Malago R, DOnofrio M, Zamboni G, Faccioli N, Falconi M, Boninsegna L . Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2009; 192(2):424-30. DOI: 10.2214/AJR.07.4043. View

Strosberg J . Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2013; 26(6):755-73. DOI: 10.1016/j.bpg.2012.12.002. View

Filosso P, Falcoz P, Solidoro P, Pellicano D, Passani S, Guerrera F . The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. J Thorac Dis. 2018; 10(Suppl 29):S3528-S3532. PMC: 6230831. DOI: 10.21037/jtd.2018.04.104. View

Falconi M, Bartsch D, Eriksson B, Kloppel G, Lopes J, OConnor J . ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012; 95(2):120-34. DOI: 10.1159/000335587. View

Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A . Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest. 2017; 40(12):1373-1380. DOI: 10.1007/s40618-017-0723-x. View

Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L . Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004; 232(2):420-30. DOI: 10.1148/radiol.2322031401. View

Massironi S, Conte D, Sciola V, Pirola L, Paggi S, Fraquelli M . Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Dig Liver Dis. 2010; 42(9):635-41. DOI: 10.1016/j.dld.2010.01.009. View

10.

Greis C . [Summary of technical principles of contrast sonography and future perspectives]. Radiologe. 2011; 51(6):456-61. DOI: 10.1007/s00117-010-2099-1. View

11.

DOnofrio M, Mansueto G, Vasori S, Falconi M, Procacci C . Contrast-enhanced ultrasonographic detection of small pancreatic insulinoma. J Ultrasound Med. 2003; 22(4):413-7. DOI: 10.7863/jum.2003.22.4.413. View

12.

Frilling A, Akerstrom G, Falconi M, Pavel M, Ramos J, Kidd M . Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012; 19(5):R163-85. DOI: 10.1530/ERC-12-0024. View

13.

Hoeffel C, Job L, Ladam-Marcus V, Vitry F, Cadiot G, Marcus C . Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Dig Dis Sci. 2008; 54(9):2040-6. DOI: 10.1007/s10620-008-0570-x. View

14.

Dorffel Y, Wermke W . Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med. 2009; 29(5):506-14. DOI: 10.1055/s-2008-1027555. View

15.

Guilmette J, Nose V . Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. Semin Diagn Pathol. 2019; 36(4):229-239. DOI: 10.1053/j.semdp.2019.03.002. View

16.

Modlin I, Oberg K, Chung D, Jensen R, de Herder W, Thakker R . Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9(1):61-72. DOI: 10.1016/S1470-2045(07)70410-2. View

17.

Strosberg J, Gardner N, Kvols L . Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009; 89(4):471-6. DOI: 10.1159/000197899. View

18.

Dromain C, Deandreis D, Scoazec J, Goere D, Ducreux M, Baudin E . Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging. 2016; 97(12):1241-1257. DOI: 10.1016/j.diii.2016.07.012. View

19.

Sidhu P, Cantisani V, Dietrich C, Gilja O, Saftoiu A, Bartels E . The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018; 39(2):e2-e44. DOI: 10.1055/a-0586-1107. View

20.

Scarsbrook A, Ganeshan A, Statham J, Thakker R, Weaver A, Talbot D . Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics. 2007; 27(2):455-77. DOI: 10.1148/rg.272065058. View